---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-030392"
form_type: "8-K"
ticker: "PLSE"
cik: "0001625101"
company_name: "PULSE BIOSCIENCES, INC."
filed_at: "2026-09-15T12:54:35+00:00"
generated_at: "2026-09-15T12:55:11.516048+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Pulse Biosciences completes 100-patient enrollment in PRECISE-BTN thyroid nodule study

## Summary
- PRECISE-BTN study of nPulse Vybrance system fully enrolled 100 patients (expanded from original 50) by August 2026.
- First enrolled patient completed final 12-month follow-up in August at Sarasota Memorial Health Care System.
- Patients enrolled across three U.S. sites: Sarasota Memorial, NYU Langone Health, Weill Cornell Medicine in about 12 months.
- Preliminary data expected at upcoming medical conference; full data after all patients complete 12-month follow-up.

## SEC filing metadata
- accession: 0001437749-26-030392
- form_type: 8-K
- ticker: PLSE
- cik: 0001625101
- company_name: PULSE BIOSCIENCES, INC.
- filed_at: 2026-09-15T12:54:35+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625101/000143774926030392/0001437749-26-030392-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625101/000143774926030392/plse20260827_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-030392
- JSON: https://secwatch.observer/filing/0001437749-26-030392.json
- Plain text: https://secwatch.observer/filing/0001437749-26-030392.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.